In January 2014, we shared our key pipeline goal for the year. Indeed, as a result of the achievements of the past period, we now believe that we will exceed our original ‘Alnylam 5×15’ guidance as issued in 2011, when we stated we expected to have 5 programs in clinical development by the end of 2015. We now expect to significantly exceed that guidance with six to seven programs in clinical development by the end of 2015, including at least two programs in Phase 3 and five to six programs that will have achieved human proof-of-concept results.
↧